1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
ORGANIZATION
API/Intermediate Imports from India Still Stalled, Traders’ Group Calls for Govt Schemes
API and intermediate imports from India are still stagnating due to logistics disruptions caused by the coronavirus pandemic, with a group of traders calling on the Indian and Japanese governments to set bilateral arrangements to facilitate trades. “If the impact…
To read the full story
Related Article
- Indian Export Restriction Lifted, but Japan Imports Still Stalled
April 10, 2020
- Big 3 Generic Maker Curbing Valsartan Shipments amid India Lockdown
April 6, 2020
- India Lockdown Derails Japan-Bound APIs, Intermediate Exports
March 30, 2020
- India’s API Export Curb Could Eventually Affect At Least 2 Firms, FPMAJ Finds
March 10, 2020
ORGANIZATION
- Generic Rate Tops 80% in All Prefectures for 1st Time in September: Payer
February 14, 2025
- US Lobbies Send Letters of Protest to Japan Embassy over Off-Year Revision, CEA
February 10, 2025
- Include Single IRB Policy in GCP to Accelerate Trials: EFPIA Official
February 10, 2025
- Role of IP Division Shifting to Partner Hunt and Dealmaking: JPMA Official
February 5, 2025
- Ex-Govt Advisor Calls for Discussions on Elective Scheme for Biologics
January 29, 2025
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…